research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
Search
for
Sort by
Research
480-510 / 1000+ results research ISID1116 – Novel androgen receptor degrader for androgenetic alopecia (AGA) application
research The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit–risk assessment of finasteride and dutasteride
Finasteride and dutasteride effectively treat hair loss, but may cause side effects like sexual dysfunction and depression.
research Role of Drug Repurposing in Sustainable Drug Discovery
Drug repurposing speeds up drug development, saves money, and has led to about a third of new drug approvals.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Inibição seletiva da 5α-redutase e preservação da aromatase no transplante capilar
A balanced approach using dutasteride and Serenoa repens can improve hair transplant success by protecting follicles and minimizing side effects.
research Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis: inositol requiring kinase 1 and c-Jun N-terminal kinase pathway
DA-9401 helps protect rat testis from finasteride damage.
research Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Afatinib often causes skin problems that need proactive management.
research BH02 Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with the AIRE gene mutation treated with ruxolitinib
Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
research Androgen receptor modulators: a review of recent patents and reports (2012-2018)
New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
research A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro
AD198 is more effective than doxorubicin in stopping certain dog cancer cells.
research Effects of 5‐alpha reductase inhibitors on lung function: A reason for discontinuation duringCOVID ‐19 pandemic?
5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research Retinoic acids shift skin stem cell fate
Retinoic acids temporarily change skin stem cells to a slower cycle and more differentiated state.
research Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis.
Using 5-alpha reductase inhibitors may increase the risk of mild depression.
research Knowledge Mapping of Drug Repositioning’s Theme and Development
Drug repositioning can save time and money but needs more support.
research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
research Androgenic Effects on Ventricular Repolarization
ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
research Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19
Four drugs were found that could potentially treat COVID-19 by inhibiting the virus in lab tests.
research Risk of rhabdomyolysis from 5-α reductase inhibitors
Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
research Antiviral Drugs Screening for Swine Acute Diarrhea Syndrome Coronavirus
Five existing drugs may help fight Swine Acute Diarrhea Syndrome Coronavirus.
research HIV and alopecia universalis
Azelaic acid's effectiveness in treating certain skin conditions needs more research.
research 5α-Reductase inhibitors in androgenetic alopecia
research Effect of 5α-reductase inhibitors on sexual function: New contributions
5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
research 24 ARQ-234: a high affinity CD200-Fc fusion protein for the treatment of atopic dermatitis
ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.
research Drug Repurposing: Accelerating New Therapeutic Discoveries from Old Molecules (1990 – 2025)
Repurposing existing drugs can quickly and cheaply find new treatments.
research A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
research Comparative Efficacy of Oral and Topical 5-Alpha Reductase Inhibitors in Reducing Dihydrotestosterone levels across Men with Androgenetic Alopecia: A Network Meta-Analysis incorporating Post-Hoc Analyses of Randomized Clinical Trial Data
Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
research Drug Repurposing for Rare Diseases
Drug repurposing offers a faster, cheaper way to find treatments for rare diseases.